Safety of Concomitant Potassium-Sparing Diuretics in Angiotensin-Converting Enzyme Inhibitor Therapy in Severe Congestive Heart Failure
| Autor: | Dietmar Glogar, Hubert Pouleur, Heinz Sochor, Gerold Porenta, Richard Pacher, Jutta Bergler-Klein |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Pharmacology
medicine.medical_specialty biology Heart disease medicine.drug_class business.industry Hemodynamics Angiotensin-converting enzyme Placebo medicine.disease Surgery chemistry.chemical_compound chemistry Internal medicine Potassium-sparing diuretic Heart failure ACE inhibitor medicine biology.protein Cardiology Xamoterol Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology. 24:194-198 |
| ISSN: | 0160-2446 |
| DOI: | 10.1097/00005344-199408000-00002 |
| Popis: | The safety of concomitant use of angiotensin-converting enzyme (ACE) inhibitors and potassium-sparing diurectics (PSD) in severe heart failure remains a controversial issue. The database of the recently reported double-blind international trial, ''Xamoterol in Severe Heart Failure,'' was investigated to elucidate this question. Of 516 patients with New York Heart Association (NYHA) class III-IV, despite diuretics and ACE inhibitor therapy, 352 were randomized to xamoterol, a beta(1) partial agonist, and 164 were randomized to placebo. During the 13-week study, 28% of all patients (xamoterol, 104; placebo, 42) received potassium-sparing diuretics. All groups were comparable in hemodynamics and dose of other diuretics. At study end, patients with or without PSD showed no significant differences in serum K+ or creatinine, independent of xamoterol or placebo therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|